These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 21068701)

  • 1. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
    Berenguer M; Aguilera V; San Juan F; Benlloch S; Rubin A; López-Andujar R; Moya A; Pareja E; Montalva E; Yago M; de Juan M; Mir J; Prieto M
    Transplantation; 2010 Dec; 90(11):1204-9. PubMed ID: 21068701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.
    Rayhill SC; Barbeito R; Katz D; Voigt M; Labrecque D; Kirby P; Miller R; Stolpen A; Wu Y; Schmidt W
    Transplant Proc; 2006 Dec; 38(10):3625-8. PubMed ID: 17175350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
    Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P; Busuttil RW; Goldstein RM; Crippin JS; Klintmalm GB; Fitzsimmons WE; Uleman C
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
    J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
    Eurich D; Neumann UP; Boas-Knoop S; Neuhaus R; Kiessling A; Yahyazadeh A; Trautwein C; Wasmuth H; Puhl G; Neuhaus P; Bahra M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):153-60. PubMed ID: 22989351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.
    Berenguer M; Royuela A; Zamora J
    Liver Transpl; 2007 Jan; 13(1):21-9. PubMed ID: 17192906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up.
    Bonaccorsi-Riani E; Sempoux C; Piette N; Julliard O; Kabamba B; Ciccarelli O; Roggen F; De Reyck C; Hassoun Z; Lerut J
    Acta Gastroenterol Belg; 2012 Dec; 75(4):411-8. PubMed ID: 23402084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.
    Aguilera V; Berenguer M; Rubín A; San-Juan F; Rayón JM; Prieto M; Mir J
    Liver Transpl; 2009 Jan; 15(1):79-87. PubMed ID: 19109849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.